Financial Markets Sap Endo

The decline in financial markets also sapped Endo International (ENDP). Endo reported remarkable Q3 results, in my opinion. The company beat on revenue and eps. Total revenue fell 5% Y/Y, which was solid given the rapid deterioration in revenue from pain-related drugs. Xiaflex and sterile injectables have created an anchor for the company. They now represent nearly 40% of total revenue. Read more:

print

LEAVE A REPLY

Please enter your comment!
Please enter your name here